FMP

FMP

Enter

NVS - Novartis AG

Financial Summary of Novartis AG(NVS), Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The compa

photo-url-https://financialmodelingprep.com/image-stock/NVS.png

Novartis AG

NVS

NYSE

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

100.53 USD

-0.58 (-0.577%)

About

ceo

Dr. Vasant Narasimhan M.D.

sector

Healthcare

industry

Drug Manufacturers - General

website

https://www.novartis.com

exchange

NYSE

Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients an...

CIK

0001114448

ISIN

US66987V1098

CUSIP

66987V109

Address

Lichtstrasse 35

Phone

41 61 324 1111

Country

CH

Employee

76,057

IPO Date

Nov 7, 1996

Summary

CIK

0001114448

Exchange

NYSE

Industry

Drug Manufacturers -...

Sector

Healthcare

CUSIP

66987V109

ISIN

US66987V1098

Country

CH

Price

100.53

Beta

0.47

Volume Avg.

1.54M

Market Cap

196.69B

Shares

-

52-Week

92.19-108.78

DCF

98.19

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

22.85

P/B

-

Website

https://www.novartis.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest NVS News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep